Trial ID or NCT#

NCT01670981

Status

RECRUITING

Purpose

This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to patients with end stage heart failure due to IDCM, who have no reasonable revascularization options (either surgical or percutaneous interventional) likely to provide clinical benefit.

Official Title

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM).

Eligibility Criteria

Ages Eligible for Study: 30 Years to 86 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Joseph C. Wu
Cardiologist
Simon H. Stertzer, MD, Professor and Professor of Radiology

Contact us to find out if this trial is right for you.

CONTACT

Karim Sallam
(650) 736-2701